Clinical Trials Browser

Ovarian Neoplasms × prexasertib × Gynecologic × Clear all

NCT02203513 2022-09-10

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Phase 2 Terminated

111 enrolled 15 charts

BreastGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome